Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study

被引:32
作者
Afif, Waqqas [1 ,2 ]
Sandborn, William J. [1 ,3 ]
Faubion, William A. [1 ]
Rahman, Meher [4 ]
Harmsen, Scott W. [5 ]
Zinsmeister, Alan R. [5 ]
Loftus, Edward V., Jr. [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] McGill Univ, Div Gastroenterol & Hepatol, Ctr Hlth, Montreal, PQ, Canada
[3] Univ Calif San Diego, Div Gastroenterol & Hepatol, La Jolla, CA 92093 USA
[4] Mayo Clin Hlth Syst, Immanuel St Josephs Specialty Clin, Gastroenterol Sect, Mankato, MN USA
[5] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA
关键词
lymphoma; immunosuppressive; anti-TNF-alpha; EPSTEIN-BARR-VIRUS; CROHNS-DISEASE; LYMPHOPROLIFERATIVE DISORDERS; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS; AZATHIOPRINE; THERAPY; INFLIXIMAB; IMMUNOSUPPRESSION; 6-MERCAPTOPURINE;
D O I
10.1097/MIB.0b013e318281325e
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background:Subgroups of patients with inflammatory bowel disease (IBD) may have an increased risk of developing lymphoma. We sought to identify factors that were associated with lymphoma in patients with IBD.Methods:Cases and controls were identified through a centralized diagnostic index. We identified 80 adult patients with IBD who developed lymphoma between 1980 and 2009. For each case, 2 controls were matched for subtype of IBD, geographic location, and length of follow-up. Conditional logistical regression was used to assess associations between risk factors and the development of lymphoma.Results:Sixty patients were males (75%) versus 77 controls (48%). Median age at index date was 59 years for cases and 42 years for controls. Twenty patients (25%) and 23 controls (14%) were receiving immunosuppressive medications at the index date. Four patients (5%) and 6 controls (4%) were receiving anti-tumor necrosis factor agents at the index date. In multiple variable analysis, age per decade (odds ratio, 1.83; 95% confidence interval, 1.37-2.43), male gender (odds ratio, 4.05; 95% confidence interval, 1.82-9.02) and immunosuppressive exposure at the index date (odds ratio, 4.20; 95% confidence interval, 1.35-13.11) were significantly associated with increased odds of developing lymphoma. Disease severity and use of anti-tumor necrosis factor agents were not independently associated with developing lymphoma. When testing was performed on patients exposed to immunosuppressive or anti-tumor necrosis factor medications, Epstein-Barr virus was identified 75% of the time.Conclusions:In this case-control study, increasing age, male gender, and use of immunosuppressive medications were associated with an increased risk of lymphoma in patients with IBD.
引用
收藏
页码:1384 / 1389
页数:6
相关论文
共 50 条
  • [41] Atherosclerosis as a Risk Factor of Inflammatory Bowel Disease: A Population-Based Case-Control Study
    Faye, Adam S.
    Axelrad, Jordan E.
    Sun, Jiangwei
    Halfvarson, Jonas
    Soderling, Jonas
    Olen, Ola
    Ludvigsson, Jonas F.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (02) : 313 - 322
  • [42] A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
    Kotlyar, David S.
    Osterman, Mark T.
    Diamond, Robert H.
    Porter, David
    Blonski, Wojciech C.
    Wasik, Mariusz
    Sampat, Sami
    Mendizabal, Manuel
    Lin, Ming V.
    Lichtenstein, Gary R.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (01) : 36 - U75
  • [43] Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study
    Biancone, Livia
    Armuzzi, Alessandro
    Scribano, Maria Lia
    Castiglione, Fabiana
    D'Inca, Renata
    Orlando, Ambrogio
    Papi, Claudio
    Daperno, Marco
    Vecchi, Maurizio
    Riegler, Gabriele
    Fries, Walter
    Alvisi, Patrizia
    Meucci, Gianmichele
    Mocciaro, Filippo
    Rogai, Francesca
    Festa, Stefano
    Guidi, Luisa
    Testa, Anna
    Spina, Luisa
    Renna, Sara
    Viola, Anna
    Patturelli, Marta
    Di Mitri, Roberto
    Frankovic, Iris
    Calabrese, Emma
    Petruzziello, Carmelina
    De Cristofaro, Elena
    Sena, Giorgia
    Ruffa, Alessandra
    Neri, Benedetto
    Rossi, Alessandra
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (03) : 450 - 459
  • [44] Isotretinoin Is Not Associated With Inflammatory Bowel Disease: A Population-Based Case-Control Study
    Bernstein, Charles N.
    Nugent, Zoann
    Longobardi, Teresa
    Blanchard, James F.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (11) : 2774 - 2778
  • [45] Immunosuppressant-associated eruptions in pediatric inflammatory bowel disease: A case-control study
    Pollard, Bruin
    Utterson, Elizabeth C.
    Samson, Charles M.
    Coughlin, Carrie C.
    PEDIATRIC DERMATOLOGY, 2022, 39 (04) : 563 - 566
  • [46] Venous Thromboembolism in Pediatric Inflammatory Bowel Disease: A Case-Control Study
    Mitchel, Elana B.
    Rosenbaum, Sara
    Gaeta, Christopher
    Huang, Jing
    Raffini, Leslie J.
    Baldassano, Robert N.
    Denburg, Michelle R.
    Albenberg, Lindsey
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2021, 72 (05) : 742 - 747
  • [47] Surgical and smoking history in inflammatory bowel disease: A case-control study
    Breslin, NP
    McDonnell, C
    OMorain, C
    INFLAMMATORY BOWEL DISEASES, 1997, 3 (01) : 1 - 5
  • [48] Clinical features of inflammatory bowel disease unclassified: a case-control study
    Shao, Yupei
    Zhao, Yixiao
    Lv, Hong
    Yan, Pengguang
    Yang, Hong
    Li, Jingnan
    Li, Ji
    Qian, Jiaming
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [49] Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study
    Lolli, Elisabetta
    Saraceno, Rosita
    Calabrese, Emma
    Ascolani, Marta
    Scarozza, Patrizio
    Chiricozzi, Andrea
    Onali, Sara
    Petruzziello, Carmelina
    Chimenti, Sergio
    Pallone, Francesco
    Biancone, Livia
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (09) : 699 - 707
  • [50] Fruit and Vegetable Consumption and Inflammatory Bowel Disease: A Case-Control Study
    Almofarreh, Anas M.
    Sheerah, Haytham A.
    Arafa, Ahmed
    Algori, Fairuz A.
    Almutairi, Ghonem R.
    Alenzi, Kafi A.
    Al-Alsehemi, Madiha M.
    Mekwar, Banan H.
    Alzeer, Osama
    Molla, Haneen N.
    LIFE-BASEL, 2024, 14 (12):